Article

Mark Zitter, MBA, Discusses Oncology Pathways

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Related Content
FDA approved | Image credit: DG-Studio – stock.adobe.com
Published: July 2nd 2025 | Updated: July 2nd 2025

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

Hayden E. Klein
This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.
Managed Care Cast
July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob
Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.
The mean percent change in body weight from the obesity cohort from baseline to 52 weeks ranged from −12.3% to −16.2% to −16.2%. | Image Credit: ricka_kinamoto - stock.adobe.com
July 1st 2025

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

Sabrina McCrear
Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.
Managed Care Cast
June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD
Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.
Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com
June 30th 2025

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

Rose McNulty
Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.
CLL cells | Image Credit: © sovova - stock.adobe.com
June 30th 2025

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

Jared Kaltwasser
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo